2012-09-17 07:09:47 - New Pharmaceuticals market report from Global Markets Direct: "Rheumatoid Arthritis - Pipeline Review, H2 2012"

Global Markets Direct's, 'Rheumatoid Arthritis - Pipeline Review, H2 2012', provides an overview of the Rheumatoid Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. 'Rheumatoid Arthritis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the

indicated disease.


Full Report Details at
- www.fastmr.com/prod/463823_rheumatoid_arthritis_pipeline_review_ ..


Scope

* A snapshot of the global therapeutic scenario for Rheumatoid Arthritis.
* A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Rheumatoid Arthritis pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Rheumatoid Arthritis therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Rheumatoid Arthritis Therapeutic Products under Development, Key Players in Rheumatoid Arthritis Therapeutics, Rheumatoid Arthritis Pipeline Overview, Rheumatoid Arthritis Pipeline, Rheumatoid Arthritis Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Rheumatoid Arthritis Overview
Therapeutics Development
An Overview of Pipeline Products for Rheumatoid Arthritis
Rheumatoid Arthritis Therapeutics under Development by Companies
Rheumatoid Arthritis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Rheumatoid Arthritis Therapeutics - Products under Development by Companies
Rheumatoid Arthritis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Rheumatoid Arthritis Therapeutics Development
Alcon, Inc.
Bristol-Myers Squibb Company
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Biogen Idec Inc.
Amgen Inc.
Antares Pharma, Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Genentech, Inc.
Inovio Biomedical Corporation
MedImmune LLC
Isis Pharmaceuticals, Inc.
Biotest AG
Merck & Co., Inc.
Santen Pharmaceutical Co., Ltd.
Ablynx
AbGenomics International, Inc.
Novo Nordisk A/S
Albany Molecular Research, Inc.
Plexxikon Inc.
BioLineRx, Ltd.
arGentis Pharmaceuticals, LLC
Reliance Life Sciences Pvt. Ltd.
MediGene AG
Celltrion, Inc.
Nycomed International Management GmbH
TiGenix NV
Pacira Pharmaceuticals, Inc.
Novartis AG
Astellas Pharma Inc.
Biocon Limited
Cephalon, Inc.
Chugai Pharmaceutical Co. Ltd
Cipla Ltd.
Daewoong Pharmaceutical Co., Ltd.
Gedeon Richter Plc.
Glenmark Pharmaceuticals Ltd.
Kissei Pharmaceutical Co., Ltd.
Mitsubishi Tanabe Pharma Corporation
MDRNA, Inc.
Pfizer Inc.
Rigel Pharmaceuticals, Inc.
Santarus, Inc.
Teva Pharmaceutical Industries Limited
Toyama Chemical Co. Ltd
UCB Group
Vertex Pharmaceuticals Incorporated
Zydus Cadila Healthcare Limited
Genmab A/S
novosom AG
Paratek Pharmaceuticals, Inc.
CEL-SCI Corporation
Celgene Corporation
Onyx Pharmaceuticals, Inc.
Merck KGaA
Bone Medical Limited

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463823&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.